ALVR stock icon

AlloVir
ALVR
Market cap $94.4M

0.8183 USD
-0.0067
0.81%
At close Oct 3, 4:00 PM EDT
1 day
-0.81%
5 days
3.58%
1 month
7.67%
3 months
11.33%
6 months
6.61%
Year to date
18.89%
1 year
-60.08%
5 years
-96.78%
 

About: AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Employees: 112

0
Funds holding %
of 6,728 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

10,000% more call options, than puts

Call options by funds: $202K | Put options by funds: $2K

2.82% less ownership

Funds ownership: 43.53% [Q1] → 40.71% (-2.82%) [Q2]

8% less capital invested

Capital invested by funds: $36.7M [Q1] → $33.9M (-$2.81M) [Q2]

8% less funds holding

Funds holding: 78 [Q1] → 72 (-6) [Q2]

30% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 20

36% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 25

Research analyst outlook

We haven’t received any recent analyst ratings for ALVR.

Financial journalist opinion

Charts implemented using Lightweight Charts™